Study Name:
A study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
Purpose of Study:
The purpose of the study is to evaluate the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.
Study Dates:
February 23, 2023 - December 31, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Vertex Pharmaceuticals Incorporated
ClinicalTrails.gov Identifier:
NCT05643495
